Momenta Pharmaceuticals Awarded Second U.S. Patent for Evaluating Mixtures of Low Molecular Weight Heparins by Chain Profiles or

Momenta Pharmaceuticals Awarded Second U.S. Patent for Evaluating Mixtures of Low Molecular Weight Heparins by Chain Profiles or Chain Mapping

CAMBRIDGE, Mass., Oct. 25, 2010 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA [1]), a biotechnology company specializing in the characterization and engineering of complex drugs, announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,816,144, entitled "Evaluating Mixtures of Low Molecular Weight Heparins By Chain Profiles or Chain Mapping". The patent includes claims to methods of analyzing and processing enoxaparin by analyzing chain sequence information.

"This patent adds to our intellectual property estate related to the characterization of enoxaparin," said Craig Wheeler, President and CEO of Momenta. "We believe this patent strengthens our portfolio of patents and pending applications that provide intellectual property protection around enoxaparin sodium injection USP, also known as generic Lovenox®."

About Enoxaparin sodium injection, USP:

Enoxaparin, a low molecular weight heparin (LMWH) is an anticoagulant that helps to prevent thrombosis. Thrombosis is the formation of a blood clot in the blood vessels in the absence of bleeding. Enoxaparin is made up of a complex blend of low molecular weight substances (oligosaccharides) derived from heparins, and therefore requires sophisticated analytical methods on the part of the manufacturer to ensure accurate and reliable characterization, development and production. Enoxaparin sodium injection USP is marketed by Momenta's collaboration partner, Sandoz, Inc., a division of Novartis.

About Momenta

Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex mixture drugs. Momenta is applying its technology to the development of generic versions of complex drug products, as well as to the discovery and development of novel drugs. Momenta was founded in 2001 based on technology initially developed at the Massachusetts Institute of Technology and is headquartered in Cambridge, MA.

To receive additional information about Momenta, please visit the website at www.momentapharma.com [2], which does not form a part of this press release.

Forward Looking Statements

Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, including statements relating to intellectual property, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "hope," "target," "project," "goals," "potential," "predict," "might," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors referred to in the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2010 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Momenta from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. Momenta is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.

CONTACT: Momenta Pharmaceuticals, Inc. Beverly Holley, Director of Investor Relations (617) 395-5189 [email protected]

Suggested Articles

Johnson & Johnson and Bayer’s Xarelto is working to reverse a sales slide, and a new indication could help.

AZ's FluMist will be dramatically limited in the U.S. this flu season because of production problems, a spokeswoman said.

To get its $12 billion opioid deal off the ground, Purdue Pharma pushed for a stay on thousands of lawsuits against it. Last week, a judge signed off.